Asia Pacific Idiopathic Pulmonary Fibrosis Industry to 2027 - by Drug Type, Distribution Channel and Country - ResearchAndMarkets.com

·3 min read

DUBLIN, May 17, 2022--(BUSINESS WIRE)--The "Asia Pacific Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The Asia Pacific Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of 8.7% CAGR during the forecast period (2021-2027).

Some persons with idiopathic pulmonary fibrosis develop more significant lung illnesses, such as lung cancer, pulmonary emboli (blood clots in the lungs), pneumonia, or excessive blood pressure in the lungs' blood vessels (pulmonary hypertension). The majority of those who are affected, live for 3 to 5 years after being diagnosed. The disease's progress, however, is highly diverse; some people get seriously ill in a matter of months, while others may live with it for a decade or longer.

IPF is a form of lung illness that causes the lungs to scar (fibrosis) for unclear reasons. As time passes, the scarring worsens, making it difficult to take a deep breath and preventing the lungs from receiving adequate oxygen. IPF is a kind of interstitial lung disease that mostly affects the interstitium (the tissue and space around the lungs' air sacs), rather than the airways or blood vessels

In the APAC region, it is discovered that the prevalence of IPF was higher in elderly people than in younger people. In 2020, approximately 30% of patients in Japan, across all age groups, were over the age of 81. As a result, growing geriatric population in various countries of the region is expected to increase the possibilities of lung-related diseases. In addition, IPF prevalence and incidence are obviously higher in older age groups, indicating that aging plays a role in the pathogenesis of IPF. Moreover, IPF appears to be more common in men than in women, however, this could be attributable to sex variations in previous smoking patterns rather than an intrinsic sex-related risk for IPF.

Due to an increase in the number of persons addicted to smoking in the Asia Pacific, the idiopathic pulmonary fibrosis market is predicted to rise significantly over the forecast period. For example, according to World Bank data from 2017, Asia Pacific accounted for almost 30% of all smokers worldwide.

The China market dominated the Asia Pacific Idiopathic Pulmonary Fibrosis Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $392.1 million by 2027. The Japan market is poised to grow at a CAGR of 8.1% during (2021 - 2027). Additionally, The India market is expected to experience a CAGR of 9.4% during (2021 - 2027).

Market Segments Covered in the Report:

By Drug Type

  • Pirfenidone

  • Nintedanib

By Distribution Channel

  • Retail Pharmacies

  • Hospital Pharmacies

  • Online Providers

By Country

  • China

  • Japan

  • India

  • South Korea

  • Singapore

  • Malaysia

  • Rest of Asia Pacific

Key Market Players

  • GNI Group Ltd.

  • Shionogi & Co., Ltd.

  • Mission Therapeutics Ltd.

  • Galapagos NV

  • FibroGen, Inc.

  • AstraZeneca PLC

  • F. Hoffmann-La Roche Ltd.

  • Bristol Myers Squibb Company

  • Boehringer Ingelheim International GmbH

  • Biogen, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/9imke

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005698/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900